30 results about "ERYTHROCYTES AGGLUTINATION" patented technology

The invention provides methods for preparing pharmaceutical formulations for injection such that upon injection the formulation does not cause erythrocyte agglutination, hemolysis, and / or cell shrinkage. To prevent agglutination, a pharmaceutical formulation ready for injection needs to have a sufficient ionic strength. To prevent hemolysis or cell shrinkage, a pharmaceutical formulation ready for injection needs to be about isotonic with respect to plasma. The invention provides methods that prepare pharmaceutical formulations for injection that have both the sufficient ionic strength to prevent agglutination and the requisite tonicity to prevent significant hemolysis or cell dehydration or shrinkage. The present methods involve the use of sodium chloride solutions that are about 25 mM to about 150 mM for reconstituting lyophilized cakes (or other non-liquid pharmaceutical formulations) into solution or for diluting pharmaceutical formulation solutions.

A process for the detection of antibodies in a test sample by preparing a suspension of erythrocytes with a test serum or plasma by mixing a test serum or plasma with erythrocytes; incubating the suspension of erythrocytes at a temperature of from 37° C. to 45° C. to bind any antibodies in the test serum or plasma to the surface of said erythrocytes; combining the suspension of erythrocytes with an amount of a solution of a macromolecule which is effective to agglutinate the erythrocytes; packing the resultant red cell agglutinates by centrifuging the suspension of erythrocytes; and, determining the presence of anti-erythrocyte antibodies by observing if antibody-dependent erythrocyte agglutination has occurred.

The invention provides a mosquito repelling and antibacterial cellulose fiber containing wormwood components, the fiber, the content of chitosan-functional component composite particles is 9.0-9.3%, and the content of silicic acid composite colloid is 2.2-2.5%; The present invention also provides a preparation method of mosquito repellent and antibacterial cellulose fiber containing wormwood components, the preparation method comprising preparation of chitosan-functional component composite particles, preparation of silicic acid composite colloid, blending, spinning and forming. The fiber prepared by the present invention has a mosquito repellent rate of 99.5-99.8%; a bacteriostasis rate of 96.7-97.3% for Candida albicans; and a erythrocyte agglutination method for influenza A virus and influenza B virus, and the titers all reach 7 -8; the fiber prepared by the present invention, the content of chitosan-functional component composite particles is 9.1-9.3%, and the content of silicic acid composite colloid is 2.2-2.5%.

The present invention provides pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity. By attaching a compound to a minus-strand RNA virus envelope protein having hemagglutinating activity, a pharmaceutical- or gene-carrier composition with lower hemagglutinating activity than a composition to which the compound has not been attached can be successfully constructed. For example, an embodiment of the present invention provides a viral vector whose erythrocyte agglutination activity and hemolytic activity are significantly lowered, and whose stability in blood is remarkably elevated. The pharmaceutical- or gene-carrier compositions provided in this invention can be preferably used for transferring pharmaceuticals or genes in vivo.

A cell analyzer and its erythrocyte agglutination alarm method and system, which measure the volume information of cells in a sample to be tested, identify cells whose volume information in the sample to be tested is greater than a preset volume threshold, obtain agglutinated red blood cell groups, and count the agglutinated red blood cell groups The number of cells was obtained to obtain the amount of erythrocyte agglutination. It is judged whether the amount of red blood cell agglutination is greater than the preset number threshold, and if the amount of red blood cell aggregation is greater than the number threshold, an alarm for red blood cell agglutination is performed. Since the agglutinated erythrocytes are identified directly according to the cell volume, it is not necessary to judge according to the content of specific components in the cells. Compared with the traditional erythrocyte agglutination alarm method, the alarm accuracy is improved, and it is simple and fast.

The invention relates to active polypeptide and a gene thereof, and application of the active polypeptide to pharmacy. Microhyla pulchra antioxidation peptide is cyclopeptide consisting of 12 pieces of amino acid, wherein the molecular weight is 1334.91 daltons; the isoelectric point is 8.002; the amino acid sequence is SEQ ID NO.1; and the third-position cysteine and the eleventh-position cysteine of the polypeptide form intramolecular disulfide bonds. The gene sequence of the microhyla pulchra antioxidation peptide consists of SEQ ID NO.4, and the gene encoded with the functional mature microhyla pulchra antioxidation peptide is the 187th to the 222nd position nucleotide. The gene of the microhyla pulchra antioxidation peptide deduces the mature functional polypeptide amino acid sequence, and the synthesized microhyla pulchra antioxidation peptide has strong erythrocyte agglutination and anti-oxidation functions.

The invention provides an avian influenza H9N2 subtype virus strain with the preservation number of CGMCC No.6757. The avian influenza H9N2 subtype virus strain provided by the invention has favorable specificity and immunogenicity, the erythrocyte agglutination effect of allantoic fluid can not be inhibited by anti-NDV (Newcastle Disease Virus) positive serum, anti-EDS76 positive serum, anti-M41 positive serum, anti-H5 subtype avian influenza virus positive serum and anti-H7 subtype avian influenza virus positive serum, but can be inhibited by H9 subtype avian influenza virus positive serum, and immunized chicken can generate an HI (Hemagglutination Inbition) antibody which is specific for H9. The avian influenza H9N2 subtype virus strain provided by the invention can be used as a vaccine strain for preventing H9 subtype avian influenza of birds, and can be used for authenticating avian influenza viruses and researching epidemiology so as to have favorable market application prospects.

The invention discloses a recombinant galactose agglutinin-1 two-string protein and a preparation method thereof. The method specifically comprises the following steps of: providing a recombinant Galectin-1 protein with bioactivity through a biotechnological method; respectively transfecting BL21 to construct engineering bacteria through constructing prokaryotic expression vectors pET-22b(+)-Gal-1 and pET-22b(+)-Gal-1 (2); and then obtaining the recombinant Galectin-1 monomer protein or a recombinant Galectin-1 two-string protein through IPTG (Isopropyl Beta-D-1-Thiogalactopyranoside) induction expression and the chromatographic separation and passivation after dividing the bacteria. Through an erythrocyte agglutination test, it is proved that both the two recombinant Galectin-1 proteins have obvious bioactivity, and the bioactivity of the Galectin-1 two-string protein is higher than that of the Galectin-1 monomer protein.

The invention discloses an attenuated strain and an inactivated vaccine of the Newcastle disease virus and application thereof, belonging to the field of separation and application of a Newcastle disease virus strain. The Newcastle disease virus attenuated strain (DL11 strain) is separated from chicken disease materials and has a microbe preservation number of CGMCC No. 7958. According to results of hemagglutination and hemagglutination inhibition tests, the separated virus strain is the Newcastle disease virus strain; and intravenous pathogenicity index determination tests prove that the virus strain is the Newcastle disease virus attenuated strain. The erythrocyte agglutination value and virus content in a semi-finished product of the separated Newcastle disease virus attenuated strain are both higher than standards prescribed in Veterinary Biological Product Regulations; and the separated Newcastle disease virus attenuated strain has low preparation cost and meets requirements for mass production. The inactivated vaccine prepared from the attenuated strain has high immune efficacy, can resist attack by a virulent strain and is applicable as a vaccine strain for prevention or diagnosis of the Newcastle disease virus.